Green tea mist tested against COVID lung inflammation in cancer patients
NCT ID NCT06924749
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested whether inhaling a green tea extract called EGCG could help cancer patients with moderate-to-severe COVID-19 pneumonia. 111 participants received either EGCG mist or a placebo three times daily for 7 days. The study looked at lung CT scan improvements, symptom relief, and safety. EGCG is known for anti-inflammatory and antiviral effects, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EGCG (epigallocatechin-3-gallate), a green tea extract, given as an inhaled mist
What this could lead to
If it works, this could offer a safe, plant-based treatment option for COVID-19 pneumonia in cancer patients, reducing lung inflammation and improving recovery.
What could go wrong
This is a small, completed Phase 2 trial with no published results yet. The benefit may be modest or not better than standard care, and the findings may not apply to non-cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanxi Zhao
Jinan, Shandong, Shandong Cancer Hospital, China
-
Shan Dong cancer hospital and institute
Jinan, Shandong, 250117, China